A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Description
All study participants will receive standard care for GBM including Temozolomide and radiation therapy. Subjects will be randomized on a 2 to 1 basis to receive either NanO2 infusions or saline infusions immediately prior to standard radiation therapy. Radiation therapy is performed 5 days a week for 6 weeks.
Radiation therapy is followed 28 days of recovery, and then six cycles of maintenance Temozolomide therapy on days 1 to 5 of six 28 day cycles.
Follow up will be every 3 months for 3 years, and then every 6 months for another 2 years.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites